Impact of Chemotherapy on Quality of Life in Advanced Colorectal Cancer
Author Information
Author(s): H Anderson, MK Palmer
Primary Institution: Christie and Wythenshawe Hospitals, Manchester, UK
Hypothesis
Raltitrexed would have similar efficacy but fewer side-effects than 5-FU, leading to improved quality of life.
Conclusion
Raltitrexed showed early advantages in quality of life compared to 5-FU plus LV, but the overall quality of life results were not significantly different.
Supporting Evidence
- Patients receiving raltitrexed had statistically significant advantages in quality of life at week 2 in several dimensions.
- Raltitrexed caused less grade 3 or 4 toxicity compared to 5-FU plus LV.
- Overall survival was significantly longer in the chemotherapy group than in the best supportive care group.
Takeaway
This study looked at how two cancer treatments affect patients' quality of life, finding that one treatment might be better at first but both have their pros and cons.
Methodology
Patients with advanced colorectal cancer were treated in two multicentre, international phase III trials comparing raltitrexed with 5-FU plus leucovorin, assessing quality of life using validated questionnaires.
Potential Biases
Potential biases due to missing data and differences in treatment schedules.
Limitations
The quality-of-life questionnaires were not administered frequently enough to detect early differences in toxicity.
Participant Demographics
Patients with advanced colorectal cancer, with a mix of performance status scores.
Statistical Information
P-Value
P = 0.0041
Confidence Interval
95% CI 1.29-3.77
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website